Cortice Biosciences Announces Upcoming Clinical Trial Presentation at the 15th Annual Meeting of the American Association for Cancer Research

NEW YORK, April 9, 2015 (GLOBE NEWSWIRE) -- Cortice Biosciences announced today that updated results from CB-017, a multi-center Phase 1/2 trial evaluating TPI 287 plus bevacizumab (Avastin®) for the treatment of patients with recurrent glioblastoma (GBM) who have not received prior bevacizumab, will be presented at the Phase 1 Clinical Trials poster session at the 15th Annual Meeting of the American Association for Cancer Research in Philadelphia, PA. Preliminary results from this study were presented last November. Results will include an additional 5 months of safety and efficacy follow-up from the first five cohorts of the dose escalation portion of the study.

Title: Interim Results From a Phase I/II Trial of TPI 287, a Novel Brain Penetrable Antimicrotubule Agent, in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Date: Tuesday, April 21
Time: 8:00 AM – 12:00 PM ET
Abstract #: 5660

About TPI 287

TPI 287 is a novel taxoid which binds to and stabilizes the assembly of microtubules similarly to commonly used taxanes, including paclitaxel (Taxol® and Abraxane®) and docetaxel (Taxotere®). In oncology treatment settings, microtubule stabilization by these agents leads to mitotic arrest and cancer cell death. TPI 287 has advantages over the taxanes due to its ability to circumvent common drug resistance mechanisms and its propensity to penetrate the central nervous system. Accordingly, TPI 287 has the potential to treat primary brain tumors and secondary brain metastases that are often shielded from systemic administration of taxanes and other chemotherapeutics. Microtubule stabilization by TPI 287 may also have potential for the treatment of neurologic disorders affected by tau protein pathology. These include tauopathies such as Alzheimer’s disease and orphan diseases, such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia.

About Glioblastoma

Glioblastoma (GBM) is the most aggressive and common form of brain cancer. Five-year survival after diagnosis is about 5%. The Central Brain Tumor Registry estimates that about 23,180 primary malignant brain tumors cases will be diagnosed in the U.S. in 2015, 46% of which will be GBM. Typical front-line treatments include stereotactic or whole brain radiotherapy plus temozolomide (Temodar®). Patients with recurrent disease are candidates for treatment with Avastin®, the last FDA approved agent for this disease.

About Cortice Biosciences

Cortice Biosciences, Inc. is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic disease indications with urgent unmet medical need. More information can be found at

Cortice Biosciences, Inc. 646-747-9090

Source: Cortice Biosciences